EMA qualifies first artificial intelligence tool to diagnose inflammatory liver disease (MASH) in biopsy samples

EMA’s human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on an innovative development methodology based on artificial intelligence (AI). The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known as non-alcoholic steatohepatitis NASH) in clinical trials. MASH is a condition where fat builds up in the liver, causing inflammation, irritation and scarrin...